Similarly, a candidate circulating CD4+ “cytotoxic” T-cell subset (GrB+PD-1+ with EM phenotype) has been identified in cHL patients, particularly in the R/R setting. The gene discussed is GZMB; the disease is classic Hodgkin lymphoma.